Drugs / Cholestyramine
Cholestyramine
also known as
Questran · A3384 · Cholestyramine light · Cholestyramine Resin · Cholybar · Colestiramina · colestyramine · Colestyramine 20 · +9 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | QUESTRAN | — | 1973-08-03 | fda.gov ↗ |
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05894928 | Jun → Jul 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04335526 | May → Jul 2020 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02963077 | Jul 2013 → May 2014 | Alagille syndrome, primary biliary cholangitis, progressive familial intrahepatic cholestasis | Albireo | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07836023 | Nov 2026 → Jun 2030 expected | — | Emory University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04235205 | Jan 2020 → Jul 2021 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Yokohama City University | Completed | No outcome recorded |
| Phase 2 | NCT04046328 | Oct 2019 → Dec 2021 | short bowel syndrome | Pharmascience Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02078856 | Mar → Dec 2014 | malabsorption syndrome | Albireo | Completed | No outcome recorded |
| Phase 2 | NCT00000461 | Dec 1986 → Nov 1992 | coronary artery disorder, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT03303053 | May 2017 → Mar 2018 | Graves disease | Clinical Research Centre, Malaysia | Unknown | No outcome recorded |
| Phase 3 | NCT00000488 | Jun 1973 → Oct 1989 | coronary artery disorder, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00000594 | Nov 1971 → Nov 1976 | coronary artery disorder, familial hypercholesterolemia, myocardial infarction, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT05966727 | Mar 2025 → Jun 2026 overdue | diabetes mellitus, obesity disorder | Centre Hospitalier Universitaire de Nice | Recruiting | No outcome recorded |
| — | NCT04003181 | Sep 2017 → May 2021 | colon adenocarcinoma, diarrheal disease | University of Aarhus | Completed | No outcome recorded |
| — | NCT02942602 | Apr 2014 → May 2016 | hyperlipidemia | Yonsei University | Completed | No outcome recorded |
| — | NCT00677469 | Jul 2007 → Jan 2008 | Graves disease | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Comparator or background therapy17 trials | ||||||
| Phase 1 | NCT06454383 Background | May 2024 → Nov 2026 expected | pancreatic ductal adenocarcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05443425 Background | Jun 2023 → Jan 2027 expected | acute graft versus host disease, hematopoietic and lymphoid system neoplasm | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT02690350 Background | Feb 2016 → Feb 2017 | hepatocellular carcinoma | Daiichi Sankyo | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02046629 Background | May → Jul 2014 | multiple sclerosis | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01239459 Background | Nov 2010 → Feb 2011 | impaired renal function disease | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT05014646 Background | Mar 2022 → Jan 2027 expected | smoldering plasma cell myeloma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02890992 Background | Sep 2016 → Sep 2018 | familial hypercholesterolemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT06141473 Background | Dec 2023 → May 2027 expected | multiple sclerosis | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03510715 Background | Aug 2018 → Feb 2020 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03510884 Background | May 2018 → Jan 2021 | hyperlipidemia | Sanofi | Completed | Met primary |
| Phase 3 | NCT01863888 Background | Oct 2013 → Jan 2015 | multiple sclerosis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00000463 Background | Apr 1987 → Dec 1998 | coronary artery disorder, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 4 | NCT05577507 Comparator | Mar → May 2023 | chronic kidney disease, hyperphosphatemia | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT02249897 Comparator | Jan 2015 → Dec 2017 | diabetic neuropathy, diabetic retinopathy, type 2 diabetes mellitus | University of Chile | Completed | No outcome recorded |
| Phase 4 | NCT01122108 Comparator | Apr → Jun 2010 | — | Louisville Metabolic and Atherosclerosis Research Center | Completed | No outcome recorded |
| Phase 4 | NCT01062269 Comparator | Jan → Feb 2010 | — | Louisville Metabolic and Atherosclerosis Research Center | Completed | No outcome recorded |
| — | NCT01053065 Comparator | — | carotid stenosis, hyperlipidemia | University of Padova | Completed | No outcome recorded |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 34 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cholestyramine | “combination With Colonic Release Cholestyramine (A3384) or Commercially Available Cholestyramine (Questran™)” NCT02963077 ↗29“Cholestyramine or Colesevelam lifelong.” NCT04003181 ↗ |
| Known as | A3384 | “combination With Colonic Release Cholestyramine (A3384) or Commercially Available Cholestyramine (Questran™)” NCT02963077 ↗ |
| Known as | Cholestyramine light | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201625 ↗ |
| Known as | Cholestyramine Resin | “Drug: Cholestyramine Resin” NCT04335526 ↗ |
| Known as | Cholybar | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201625 ↗ |
| Known as | Colestiramina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201625 ↗ |
| Known as | colestyramine | “along with colestyramine or equivalent if clinically indicated” NCT02690350 ↗ |
| Known as | Colestyramine 20 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201625 ↗ |
| Known as | CTM | “EXB and cholestyramine (CTM) facilitate the removal of free cholesterol from the liver by decreasing BA recirculation to the liver, thereby stimulating novel BA synthesis from...” PMID 32907904 ↗ Sep 2020 |
| Known as | Cuemid | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201625 ↗ |
| Known as | Duolite ap143 resin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201625 ↗ |
| Known as | ECC | “Enteric-Coated Cholestyramine (ECC) Capsule” NCT04046328 ↗ |
| Known as | Enteric-Coated Cholestyramine (ECC) Capsule | “Enteric-Coated Cholestyramine (ECC) Capsule” NCT04046328 ↗ |
| Known as | Locholest | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201625 ↗ |
| Known as | Locholest light | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201625 ↗ |
| Known as | Prevalite | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201625 ↗ |
| Known as | Questran | “combination With Colonic Release Cholestyramine (A3384) or Commercially Available Cholestyramine (Questran™)” NCT02963077 ↗3“cholestyramine (Questran, Bristol Myer Squibb) 8 g/day plus sitosterol (Unilever) 2.5 g/day” NCT01053065 ↗ “orange-flavored generic Questran (cholestyramine)” NCT01062269 ↗ “Cholestyramine Resin 4000 MG [Questran]” NCT05577507 ↗ |
| Known as | Questran light | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201625 ↗ |
| Modality | Other / unclassified | “Cholestyramine, an ionic exchange resin sequesters T4 in the intestine and increases its fecal excretion.” NCT00677469 ↗ |
| Route | Oral | “In all of these trials, cholestyramine was dosed at 4 grams orally two to four times a day.” NCT00677469 ↗ |